{
  "id": "52fc94db2059c6d71c000074",
  "type": "list",
  "question": "List anti-amyloid-beta monoclonal antibodies that have been investigated in clinical trials for treatment of Alzheimer disease.",
  "ideal_answer": "Ponezumab, solanezumab and bapineuzumab are humanized antiamyloid beta (A\u03b2) monoclonal antibodies that have been designed for treatment of Alzheimer disease.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/21784350",
    "http://www.ncbi.nlm.nih.gov/pubmed/20189881",
    "http://www.ncbi.nlm.nih.gov/pubmed/23334069",
    "http://www.ncbi.nlm.nih.gov/pubmed/21263194",
    "http://www.ncbi.nlm.nih.gov/pubmed/22277519",
    "http://www.ncbi.nlm.nih.gov/pubmed/20360050",
    "http://www.ncbi.nlm.nih.gov/pubmed/20505438",
    "http://www.ncbi.nlm.nih.gov/pubmed/21504387",
    "http://www.ncbi.nlm.nih.gov/pubmed/19923550",
    "http://www.ncbi.nlm.nih.gov/pubmed/22473769",
    "http://www.ncbi.nlm.nih.gov/pubmed/21091109",
    "http://www.ncbi.nlm.nih.gov/pubmed/21592055",
    "http://www.ncbi.nlm.nih.gov/pubmed/23334070",
    "http://www.ncbi.nlm.nih.gov/pubmed/21987394",
    "http://www.ncbi.nlm.nih.gov/pubmed/16338209",
    "http://www.ncbi.nlm.nih.gov/pubmed/23574434",
    "http://www.ncbi.nlm.nih.gov/pubmed/20205639",
    "http://www.ncbi.nlm.nih.gov/pubmed/22134132",
    "http://www.ncbi.nlm.nih.gov/pubmed/20154508",
    "http://www.ncbi.nlm.nih.gov/pubmed/23796662",
    "http://www.ncbi.nlm.nih.gov/pubmed/21883222",
    "http://www.ncbi.nlm.nih.gov/pubmed/22339463",
    "http://www.ncbi.nlm.nih.gov/pubmed/22292124",
    "http://www.ncbi.nlm.nih.gov/pubmed/20375655",
    "http://www.ncbi.nlm.nih.gov/pubmed/19228370",
    "http://www.ncbi.nlm.nih.gov/pubmed/19585948"
  ],
  "snippets": [
    {
      "text": "The first active immunization clinical trial with AN1792 in AD patients was halted when a subset of patients developed meningoencephalitis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20205639",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The first passive immunotherapy trial with bapineuzumab,",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20205639",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Preliminary results of a prematurely terminated clinical trial where AD patients were actively vaccinated with aggregated Abeta ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/16338209",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "strategies based on A\u03b21-42 peptide induced encephalomyelitis and possible microhemorrhages.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23796662",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Phase III trials showed that bapineuzumab failed to improve cognitive and functional performances in AD patients, and was associated with a high incidence of amyloid-related imaging abnormalities (ARIA).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23574434",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Solanezumab's two Phase III trials in AD patients failed to meet endpoints when analyzed independently. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23574434",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Unfortunately, the first active vaccine (AN1792, consisting of preaggregate A\u03b2 and an immune adjuvant, QS-21) was abandoned because it caused meningoencephalitis in approximately 6% of treated patients",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22339463",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Anti-A\u03b2 monoclonal antibodies (bapineuzumab and solanezumab) are now being developed.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22339463",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "several monoclonal and polyclonal antibodies are in clinical trials. These are bapineuzumab, solanezumab, ponezumab, gantenerumab, BAN2401, gammaguard and octagam. Since each antibody has a different antigen epitope of Abeta, anti-amyloid activities are different.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22277519",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Several types of A\u03b2 peptide immunotherapy for Alzheimer's disease are under investigation, direct immunization with synthetic intact A\u03b2(42) , active immunization involving the administration of synthetic fragments of A\u03b2 peptide conjugated to a carrier protein and passive administration with monoclonal antibodies directed against A\u03b2 peptide",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21883222",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "An active anti-A\u03b2 vaccine preparation, AN1792, has been used in AD patients with some clues of clinical efficacy but causing meningoencephalitis in about 6% of patients and it has been abandoned",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21592055",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The most advanced of these immunological approaches is bapineuzumab, composed of humanized anti-A\u03b2 monoclonal antibodies, that has been tested in two Phase II trials, demonstrating to reduce A\u03b2 burden in the brain of AD patients. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21592055",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The results of four ongoing large Phase III trials on bapineuzumab will tell us if passive anti-A\u03b2 immunization is able to alter the course if this devastating disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21592055",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Solanezumab is a monoclonal antibody that binds to \u03b2-amyloid (A\u03b2), a protein that plays a key role in the pathogenesis of AD. The drug is currently being investigated in Phase III trials as a disease-modifying treatment for AD. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21504387",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The most advanced of these immunological approaches is bapineuzumab, which is composed of humanized anti-A\u03b2 monoclonal antibodies that has been tested in two Phase II trials. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21091109",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The results of four ongoing large Phase III trials on bapineuzumab will provide answers regarding whether passive anti-A\u03b2 immunization is able to alter the course of this devastating disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21091109",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [
    "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000544",
    "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016430",
    "http://www.disease-ontology.org/api/metadata/DOID:10652",
    "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000911",
    "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016229",
    "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016032",
    "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D002986"
  ],
  "exact_answer": "Bapineuzumab, bapineuzumab, Solanezumab, solanezumab, Ponezumab, ponezumab, Gantenerumab"
}